Page 57 - Read Online

Page 187 Vojdeman et al. J Transl Genet Genom 2021;5:182-88 https://dx.doi.org/10.20517/jtgg.2021.03

Analysed the data: Vojdeman FJ, Pedersen LB, van Norden Y
Wrote the paper: Vojdeman FJ, Niemann CU
All authors have commented and approved the manuscript.

Availability of data and materials
All data is available upon specific inquiry to Vojdeman FJ.

Financial support and sponsorship
Niemann CU: Novo Nordisk Foundation NNF16OC0019302, Danish Cancer Society.

Conflicts of interest
Vojdeman FJ, Pedersen LB, te Raa D, Juvonen V, van Norden Y, Itälä-Remes M, Rosenquist R, Evers LM,
Zenz T, van Oers MHJ, Geisler CH declared that there are no conflicts of interest.
Tjønnfjord GE: advisory board (Abbvie) and Lecture honoraria (Janssen Cilag).
Kimby E: advisory board: Roche, Celgene, Janssen, Abbvie, Phizer, Mei Pharma. Educational lectures:
Gilead, Roche, Celgene, Janssen, Abbvie. Research funding: Phizer.
Langerak AW: research funding (Roche-Genentech and Gilead), advisory committee (AbbVie), lecture
honoraria (Janssen).
Walewski J: advisory role: Roche, Celgene, Takeda, Janssen-Cilag, Servier, Amgen, BMS, Incyte; research
funding: Roche, GSK/Novartis, Takeda, Janssen-Cilag, Abbvie; lecture honoraria: Roche, Celgene, Takeda,
Janssen-Cilag, Servier; travel support: Roche.
Kater AP: research grants Abbvie, Janssen, Roche, Celgene.
Niemann CU: support outside the present study: Roche, Gilead, Janssen, Abbvie, Novartis, CSL Behring,
AstraZeneca, Acerta, Sunesis.

Ethical approval and consent to participate
[2]
The HOVON 68 study was approved by the national ethical comitees as described in (Geisler et al. 2014).

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Jaramillo S, Agathangelidis A, Schneider C, et al. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets:
analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica 2020;105:2598-607. DOI
PubMed PMC
2. Geisler CH, van T' Veer MB, Jurlander J, et al. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs
progression-free survival in high-risk CLL. Blood 2014;123:3255-62. DOI PubMed
3. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a
molecular classification with implications for targeted therapies. Blood 2012;119:4467-75. DOI PubMed PMC
4. Agathangelidis A, Chatzidimitriou A, Gemenetzi K, et al. Higher-order connections between stereotyped subsets: implications for
improved patient classification in CLL. Blood 2021;137:1365-76. DOI PubMed PMC
5. Baliakas P, Hadzidimitriou A, Sutton L, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic
leukaemia: a retrospective multicentre study. Lancet Haematol 2014;1:e74-84. DOI PubMed
6. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted
Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003;101:4952-7. DOI
PubMed
7. Bystry V, Agathangelidis A, Bikos V, et al; European Research Initiative on CLL. ARResT/AssignSubsets: a novel application for
robust subclassification of chronic lymphocytic leukemia based on B cell receptor IG stereotypy. Bioinformatics 2015;31:3844-6. DOI
PubMed
8. Jethwa A, Hüllein J, Stolz T, et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic